Catalog
Disorders due to substance use
No MMS code
Link to WHO Definition
Disorders due to substance use – http://id.who.int/icd/entity/590211325
Disorders due to substance use include disorders that result from a single occasion or repeated use of substances that have psychoactive properties, including certain medications. Disorders related to fourteen classes or groups of psychoactive substances are included. Typically, initial use of these substances produces pleasant or appealing psychoactive effects that are rewarding and reinforcing with repeated use. With continued use, many of the included substances have the capacity to produce dependence. They also have the potential to cause numerous forms of harm, both to mental and physical health. Disorders due to harmful non-medical use of non-psychoactive substances are also included in this grouping.
Parents
Children
- 6C46 Disorders due to use of stimulants including amphetamines, methamphetamine or methcathinone
- 6C43 Disorders due to use of opioids
- 6C4C Disorders due to use of methylene-dioxymethamphetamine [MDMA] or related drugs, including methylene-dioxyamphetamine [MDA]
- 6C4E Disorders due to use of other specified psychoactive substances, including medications
- 6C4G Disorders due to use of unknown or unspecified psychoactive substances
- 6C47 Disorders due to use of synthetic cathinones
- 6C40 Disorders due to use of alcohol
- 6C45 Disorders due to use of cocaine
- 6C4B Disorders due to use of volatile inhalants
- 6C41 Disorders due to use of cannabis
- 6C49 Disorders due to use of hallucinogens
- 6C4H Disorders due to use of non-psychoactive substances
- 6C4A Disorders due to use of nicotine
- 6A41 Catatonia induced by substances or medications
- 6C48 Disorders due to use of caffeine
- 6C44 Disorders due to use of sedatives, hypnotics or anxiolytics
- 6C4D Disorders due to use of dissociative drugs including ketamine or phencyclidine (PCP)
- 6C4F Disorders due to use of multiple specified psychoactive substances, including medications
- 6C42 Disorders due to use of synthetic cannabinoids